SCA Clinical Trial - Encouraging New Data
The podcast below is from the annual NAF Meeting in Las Vegas, March, 2019 and features Gil L’Italien, PhD, Head of GHEOR and Epidemiology and Melissa Wolfe Beiner, MD, Director of Research and Development and Ataxia Medical Lead, both from Biohaven Pharmaceuticals.
They highlight some important and encouraging new data from an expanded analysis of their data from their first clinical trial of troriluzole in SCA patients. This clinical trial was the first registrational trial in SCA patients in the United States. This work reflects a collaboration between Biohaven and numerous experts in the ataxia field across the country.